|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"lin z z"
Showing items 296-305 of 330 (33 Page(s) Totally)
<< < 24 25 26 27 28 29 30 31 32 33 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2020 |
Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer
|
Kuo S.-H.; Cheng A.-L.; Yang J.C.-H.; Lu S.-H.; Lin Z.-Z.; Yu C.-J.; JIN-YUAN SHIH; Chen Y.-H.; Hsu F.-M.; Yang W.-C.; Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Jin-Yuan Shih;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Kuo S.-H. |
| 臺大學術典藏 |
2020 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; CHIUN HSU |
| 臺大學術典藏 |
2019 |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Lu L.-C.; Shen Y.-C.; Chiun Hsu; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Liu T.-H.; Shao Y.-Y. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yao Z.-H.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; JIN-YUAN SHIH; Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Jin-Yuan Shih;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Lin C.-C.; Chen J.-S.; Lin Z.-Z. |
| 臺大學術典藏 |
2019 |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients
|
Yu C.-J.; Yang J.C.-H.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Shih J.-Y.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yao Z.-H.; Yao Z.-H.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J. |
| 臺大學術典藏 |
2019 |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.; CHIUN HSU; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 國立成功大學 |
2019 |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin, S.;Chan, S.L.;Sukeepaisarnjaroen, W.;Han, G.;Choo, S.P.;Sriuranpong, V.;Pan, H.;Yau, T.;Guo, Y.;Chen, M.;Ren, Z.;Xu, J.;Yen, C.-J.;Lin, Z.-Z.;Manenti, L.;Gu, Y.;Sun, Y.;Tiedt, R.;Hao, L.;Song, W.;Tanwandee, Tanwandee T. |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 臺大學術典藏 |
2018-09-10T18:05:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y.-Y.;Chen, B.-B.;Ou, D.-L.;Lin, Z.-Z.;Hsu, C.-H.;Wang, M.-J.;Cheng, A.-L.;Hsu, C.; BANG-BIN CHEN; ANN-LII CHENG |
| 臺大學術典藏 |
2018-09-10T07:20:08Z |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment
|
Huang, C.-L.;Yang, C.-H.;Yeh, K.-H.;Hu, F.-C.;Chen, K.-Y.;Shih, J.-Y.;Lin, Z.-Z.;Yu, C.-J.;Cheng, A.-L.;Yang, P.-C.; Chong-Jen Yu; KUN-HUEI YEH; JIN-YUAN SHIH; ANN-LII CHENG |
Showing items 296-305 of 330 (33 Page(s) Totally)
<< < 24 25 26 27 28 29 30 31 32 33 > >>
View [10|25|50] records per page
|
